- Home
- ARBE vs NRXS Comparison
ARBE vs NRXS Comparison
Compare ARBE & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ARBE | NRXS |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.1M | 78.9M |
| IPO Year | 2021 | 2023 |
Fundamental Metrics
Financial Performance| Metric | ARBE | NRXS |
|---|---|---|
| Price | $0.67 | $7.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $2.38 | ★ $13.00 |
| AVG Volume (30 Days) | ★ 3.1M | 117.8K |
| Earning Date | 05-19-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,569,282.00 |
| Revenue This Year | $363.94 | $172.91 |
| Revenue Next Year | $286.43 | $115.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.89 |
| 52 Week Low | $0.55 | $2.21 |
| 52 Week High | $2.88 | $9.33 |
Technical Indicators
Market Signals| Indicator | ARBE | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 44.84 | 71.91 |
| Support Level | $0.60 | $6.44 |
| Resistance Level | $0.89 | $7.54 |
| Average True Range (ATR) | 0.06 | 0.37 |
| MACD | -0.00 | 0.22 |
| Stochastic Oscillator | 16.24 | 80.18 |
Price Performance
Historical ComparisonAbout ARBE Arbe Robotics Ltd.
Arbe Robotics Ltd is a provider of 4D Imaging Radar solutions enabling driver-assist systems while paving the way for fully autonomous driving. It is a research and development company in the field of chips for Advanced radar systems, which are mainly intended to be used as Advanced Driver Assistance Systems (ADAS) adapted for autonomous vehicles as well as for non-automotive uses. Its geographical segments include Sweden, China, Germany, Hong Kong, USA, Israel, Switzerland, Italy, and others.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).